The intracellular signalosome of PD-L1 in cancer cells

被引:220
作者
Escors, David [1 ,2 ]
Gato-Canas, Maria [1 ]
Zuazo, Miren [1 ]
Arasanz, Hugo [1 ,3 ]
Jesus Garcia-Granda, Maria [1 ]
Vera, Ruth [3 ]
Kochan, Grazyna [1 ]
机构
[1] Complejo Hosp Navarra, IdISNA, Navarrabiomed, Irunlarrea 3, Pamplona 31008, Navarra, Spain
[2] UCL, Rayne Inst, Div Infect & Immun, 5 Univ St, London WC1E 6JF, England
[3] Complejo Hosp Navarra, IdISNA, Oncol Dept, Irunlarrea 3, Pamplona 31008, Navarra, Spain
关键词
T-CELLS; B7-H1; EXPRESSION; TUMOR-CELLS; B7; FAMILY; IFN-GAMMA; PROGRAMMED CELL-DEATH-1; ACQUIRED-RESISTANCE; SIGNALING PATHWAYS; CARCINOMA PATIENTS; DOWN-MODULATION;
D O I
10.1038/s41392-018-0022-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Programmed cell death-1 ligand-1 (PD-L1) overexpression in cancer cells accelerates tumor progression. PD-L1 possesses two main pro-oncogenic functions. First, PD-L1 is a strong immunosuppressive molecule that inactivates tumor-specific T cells by binding to the inhibitory receptor PD-1. Second, PD-L1 function relies on the delivery of intrinsic intracellular signals that enhance cancer cell survival, regulate stress responses and confer resistance toward pro-apoptotic stimuli, such as interferons. Here, we review the current knowledge on intracellular signal transduction pathways regulated by PD-L1, describe its associated signalosome and discuss potential combinations of targeted therapies against the signalosome with PD-L1/PD-1 blockade therapies.
引用
收藏
页数:9
相关论文
共 113 条
[1]   IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer [J].
Abiko, K. ;
Matsumura, N. ;
Hamanishi, J. ;
Horikawa, N. ;
Murakami, R. ;
Yamaguchi, K. ;
Yoshioka, Y. ;
Baba, T. ;
Konishi, I. ;
Mandai, M. .
BRITISH JOURNAL OF CANCER, 2015, 112 (09) :1501-1509
[2]   EGFR TKI combination with immunotherapy in non-small cell lung cancer [J].
Ahn, Myung-Ju ;
Sun, Jong-Mu ;
Lee, Se-Hoon ;
Ahn, Jin Seok ;
Park, Keunchil .
EXPERT OPINION ON DRUG SAFETY, 2017, 16 (04) :465-469
[3]  
Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745
[4]   PD1 signal transduction pathways in T cells [J].
Arasanz, Hugo ;
Gato-Canas, Maria ;
Zuazo, Miren ;
Ibanez-Vea, Maria ;
Breckpot, Karine ;
Kochan, Grazyna ;
Escors, David .
ONCOTARGET, 2017, 8 (31) :51936-51945
[5]  
Arasanz H, 2017, MELANOMA MANAG, V4, P39, DOI 10.2217/mmt-2016-0019
[6]   B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells [J].
Azuma, Takeshi ;
Yao, Sheng ;
Zhu, Gefeng ;
Flies, Andrew S. ;
Flies, Sarah J. ;
Chen, Lieping .
BLOOD, 2008, 111 (07) :3635-3643
[7]   Restoring function in exhausted CD8 T cells during chronic viral infection [J].
Barber, DL ;
Wherry, EJ ;
Masopust, D ;
Zhu, BG ;
Allison, JP ;
Sharpe, AH ;
Freeman, GJ ;
Ahmed, R .
NATURE, 2006, 439 (7077) :682-687
[8]   Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].
Bellmunt, J. ;
de Wit, R. ;
Vaughn, D. J. ;
Fradet, Y. ;
Lee, J. -L. ;
Fong, L. ;
Vogelzang, N. J. ;
Climent, M. A. ;
Petrylak, D. P. ;
Choueiri, T. K. ;
Necchi, A. ;
Gerritsen, W. ;
Gurney, H. ;
Quinn, D. I. ;
Culine, S. ;
Sternberg, C. N. ;
Mai, Y. ;
Poehlein, C. H. ;
Perini, R. F. ;
Bajorin, D. F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026
[9]   Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro [J].
Blank, C ;
Kuball, J ;
Voelkl, S ;
Wiendl, H ;
Becker, B ;
Walter, B ;
Majdic, O ;
Gajewski, TF ;
Theobald, M ;
Andreesen, R ;
Mackensen, A .
INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (02) :317-327
[10]   Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy [J].
Blank, C ;
Gajewski, TF ;
Mackensen, A .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (04) :307-314